SM
BCLI

Sabby Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Sabby Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7
Closed -$2.12K – 61
2023
Q3 		$2.12K Hold
7
– – ﹤0.01% 84
2023
Q2 		$21.8K Buy
+7
New +$290 0.02% 82
2022
Q1 		– Sell
-345
Closed -$2.07M – 155
2021
Q4 		$2.07M Buy
345
+16
+5% +$788 0.3% 52
2021
Q3 		$1.63M Buy
329
+15
+5% +$789 0.22% 60
2021
Q2 		$1.79M Buy
314
+19
+6% +$1.01K 0.25% 61
2021
Q1 		$1.69M Buy
295
+137
+87% +$10.3K 0.33% 59
2020
Q4 		$1.07M Sell
158
-138
-47% -$18.8K 0.21% 48
2020
Q3 		$7.52M Sell
296
-326
-52% -$66.8K 1.12% 20
2020
Q2 		$33.2M Buy
622
+353
+131% +$38.1K 6.66% 5
2020
Q1 		$1.88M Buy
269
+130
+94% +$10.1K 0.78% 18
2019
Q4 		$894K Sell
139
-35
-20% -$2.03K 0.25% 20
2019
Q3 		$1.02M Buy
174
+41
+31% +$2.42K 0.55% 21
2019
Q2 		$532K Buy
+133
New +$7.74K 0.67% 31

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Sabby Management's BCLI Position: Q4 2023 in Review

Sabby Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2023, closing a stake of 9,099 shares — an estimated $27.3K sold.

Sabby Management first reported a position in BCLI in Q3 2014 and held it in 23 quarters. The position peaked at $6.27M in Q1 2015. 46 funds tracked by Wall St. Rank hold BCLI as of Q4 2023.

  • Sabby Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2023 after selling out during the quarter.
  • Sabby Management sold 9,099 BRAINSTORM CELL THERAPUTC shares in Q4 2023, an estimated $27.3K.
  • Sabby Management first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2014 and held it in 23 quarters.
  • Sabby Management's BRAINSTORM CELL THERAPUTC position peaked at $6.27M in Q1 2015.
  • 46 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2023.

Based on Sabby Management's 13F filing for Q4 2023, filed 14 Feb 2024.